| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Bezisterim | HE-3286; NE-3107 | Phase 3 Clinical | Harbor Therapeutics, Biovie Inc | Diabetes Mellitus, Type 2; Brain Injuries, Traumatic; Insulin Resistance; Arthritis, Rheumatoid; Post-Acute COVID-19 Syndrome; Alzheimer Disease; Colitis, Ulcerative; Parkinson Disease | Details |
| PN-235 | JNJ-77242113; PN-235; JNJ-2113; PN-21235; JNJ-77242113-AAC | Phase 3 Clinical | Protagonist Therapeutics Inc | Psoriasis; Colitis, Ulcerative; Plaque psoriasis | Details |
| PN-232 | PN-232; JNJ75105186 | Phase 1 Clinical | Protagonist Therapeutics Inc | Details |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Ustekinumab biosimilar (Samsung Bioepis) | SB-17; SB17 | Approved | Samsung Bioepis Co Ltd | Pyzchiva | EU | Crohn Disease; Colitis, Ulcerative | Samsung Bioepis Nl Bv | 2024-04-19 | Gastrointestinal Diseases; Skin Diseases; Psoriasis; Arthritis, Psoriatic; Rheumatic Diseases; Colitis, Ulcerative; Inflammation; Crohn Disease; Plaque psoriasis | Details |




